Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Reardon, David
Item TypeName
Academic Article Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Academic Article Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Academic Article A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
Academic Article Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
Academic Article Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Academic Article Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Academic Article Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Academic Article Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Academic Article A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Academic Article Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Academic Article Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Academic Article Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Academic Article Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Academic Article Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Academic Article Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Academic Article Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Academic Article Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Academic Article Bevacizumab and daily temozolomide for recurrent glioblastoma.
Academic Article Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Academic Article A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Academic Article Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Academic Article Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Academic Article A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Academic Article Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Academic Article Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Academic Article Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Academic Article Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.
Academic Article Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Academic Article Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Academic Article Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Academic Article Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years.
Academic Article Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Academic Article Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Academic Article Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Academic Article Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Academic Article Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Academic Article Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Academic Article Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Academic Article Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Academic Article Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
Academic Article Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Academic Article Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Academic Article Phase II trial of gefitinib in recurrent glioblastoma.
Academic Article Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Academic Article Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Academic Article Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Academic Article Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Academic Article Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
Academic Article Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Concept Neoplasm Recurrence, Local
Concept Recurrence
Academic Article Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Academic Article Malignant evolution of choroid plexus papilloma.
Academic Article Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Academic Article Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Academic Article Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.
Academic Article Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Academic Article Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Academic Article Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Academic Article Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?
Academic Article Brachytherapy in the treatment of recurrent aggressive falcine meningiomas.
Academic Article A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Academic Article Multicentric Low-Grade Gliomas.
Academic Article The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Academic Article Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Academic Article Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Grant Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
Academic Article Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Academic Article Angiogenesis inhibitors in tackling recurrent glioblastoma.
Academic Article Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Academic Article Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Academic Article Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Academic Article Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
Academic Article Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Academic Article Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Academic Article Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
Academic Article Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Academic Article Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Academic Article Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.
Academic Article Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Academic Article PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Academic Article Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
Academic Article Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Academic Article Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Search Criteria
  • Recurrence
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.